Introduction
Chronic myelogenous leukemia (CML) is caused by the Philadelphia chromosome translocation t(9;22) (q34;q11), which fuses the bcr and the c-abl genes (Wong and Witte, 2004) . The resulting p210 Bcr-Abl protein is a constitutively active tyrosine kinase, phosphorylating a variety of substrates that activate multiple signaling pathways, including among others phosphatidylinositol 3-kinase (PI3K), Janus kinase (JAK)/signal transducers and activator of transcription (STAT) and the Ras/MAP kinase/ERK kinase (MEK)/ extracellular signal-regulated protein kinase (Erk)1/2 pathways, thus conferring growth factor-independent proliferation and survival of myeloid progenitor cells (Deininger et al., 2000; Steelman et al., 2004) . Imatinib mesylate (Gleevec, STI571) has emerged as the lead compound to treat the chronic phase of CML (O'Brien et al., 2003) . It is well established that the drug targets the ATP-binding site of Bcr-Abl, thereby inhibiting its tyrosine kinase activity (Roskoski, 2003) .
Other molecules that bind to Bcr-Abl such as PD166326 also act as efficient inhibitors of the oncogenic tyrosine kinase (Wolff et al., 2005) . Following drug treatment, the Bcr-Abl protein is rapidly dephosphorylated and inactivated, leading to the blocking of the above-mentioned signaling cascades. Subsequently, the cell cycle progression is impaired and cells undergo an apoptotic programme characterized by activation of caspases 9, 8 and 3 (Jacquel et al., 2003) . Furthermore, it has been recently shown that inhibition of caspases in imatinib-treated K562 cells shifted the cells from a caspase-dependent to a necrosis-like cell death process, suggesting that imatinib also triggered caspase-independent cell death (CID) (Okada et al., 2004) .
Increasing evidence also indicates that besides their recognized role in the initiation and completion of apoptosis, caspases also play a regulatory function in hematopoietic cell proliferation and differentiation. In this line, erythroid differentiation in the bone marrow has been shown to involve caspase-dependent processes (Zermati et al., 2001; Kolbus et al., 2002; Carlile et al., 2004) .
The human K562 cell line is widely used as a model for leukemia differentiation (Belhacene et al., 1998; Racke et al., 2001; Jacquel et al., 2006) . Interestingly, it expresses the p210 Bcr-Abl protein and can also be induced to differentiate towards the megakaryocytic or erythroid lineages depending on the stimuli and, therefore, represents an appropriate cellular model to study the relationships between apoptotic and differentiation program in leukemia (Dorsey et al., 2002; Jacquel et al., 2003; Pettiford and Herbst, 2003; Kawano et al., 2004) . We and others have recently shown that besides inducing apoptosis in K562 cells, imatinib also triggered erythroid differentiation of this cell line increasing its hemoglobin content and the expression of glycophorin A (GPA), and other specific erythroid markers at the cell surface (Kohmura et al., 2004; Kuzelova et al., 2005) . However, despite extensive studies, the types of cell death used by imatinib and other Bcr-Abl-inhibiting compounds to kill Ph þ cells remains only partially elucidated even though caspase-dependent and -independent processes have been evidenced. Another interesting and unresolved question concerns the influence that differentiation and cell death may have on each other in imatinib-treated CML cells.
In the present study, we demonstrated that imatinib and PD166326, two Bcr-Abl inhibitors, induced caspase-dependent cell death in CML cell lines and that apoptosis and erythroid differentiation are two independent processes that can be easily dissociated. Finally, our results also indicated that both processes can be distinguished on the basis of their caspase dependence. The notion that Bcr-Abl-mediated cell death and erythroid differentiation are independent events may have interesting applications in the future for the treatment of CML.
Results

Bcr-Abl inhibitors induced caspase activation and cell death in K562 cells
Imatinib and PD166326 induced a very similar profile of caspase activation and inhibition of cell viability after a 48 h treatment of the K562 CML cell line. However, PD166326 was found to be at least 300 times more effective than imatinib ( Figure 1a ) with a half-maximal modulation for both effects in the nanomolar range in accordance with previous results from the literature (Huron et al., 2003; Wolff et al., 2005) . As imatinibmediated cell death is thought to be a caspase-dependent event, we analysed the effect of ZVAD-fmk on imatinib and PD166326-mediated caspase activation. As illustrated on Figure 1b , ZVAD-fmk was found to abolish Bcr-Abl inhibitor-induced caspase activation. Externalization of phosphatidylserine was next followed by annexin V binding. The number of annexin V-positive cells reached from 10% in control cells to 60% in imatinib or PD166326-treated cells, and ZVAD-fmk decreased the number of annexin V cells to approximatively 30% in the presence of the Bcr-Abl inhibitors (Figure 1c ).
Cell metabolism was next assessed by the sodium 3 0 -(l-(phenylaminocarbonnyl)-3,4-tetrazolium)-bis-acid(4-methoxy-6-nitro)benzen sulfonic acid hydrat (XTT) assay at different times and various drug concentrations. A 24 h treatment with the Bcr-Abl inhibitor induced a Imatinib mesylate and PD166326 induce apoptosis and decreased cell metabolism in K562 cells. (a) Caspase activity was assessed on lysates prepared from cells stimulated for 48 h with increasing concentrations of imatinib or PD166326 by using 0.2 mM Ac-DEVD-pNa as substrate. Substrate hydrolysis was determined at 405 nm. To assess specific caspase activity, hydrolysis was followed at different times in the presence or absence of 10 mM Ac-DEVD-CHO. The surviving cells were quantitated by XTT assay as described in the Materials and methods section. Results are expressed as percentage of response and represent the mean7s.d. of four different determinations. (b) Caspase activity was assessed on lysates prepared from cells stimulated for 48 h with increasing concentrations of imatinib or PD166326 in the presence or absence of 50 mM ZVAD-fmk using 0.2 mM Ac-DEVD-AMC as substrate. Ac-DEVD-AMC hydrolysis was determined following emission at 460 nm after excitation at 390 nm. To assess specific caspase activity, hydrolysis was followed at different times in the presence or absence of 10 mM Ac-DEVD-CHO. Results are expressed as arbitrary units and represent the mean7s.d. of four different determinations. (c) Cells were treated for 48 h with imatinib or PD166326 in the presence or absence of 50 mM ZVADfmk. Cells were then stained with Annexin-V-fluos staining kit according to the manufacturer's indications. A representative experiment is shown.
Bcr-Abl, apoptosis and erythroid differentiation A Jacquel et al dose-dependent loss of cell metabolism which reached 30% of the control value at the highest drug concentration and was not affected by caspase inhibition (Figure 2a) . After 48 and 72 h in the presence of the drugs, XTT metabolism dropped to only 30 and 20%, respectively, and ZVAD-fmk was found to increase cell metabolism significantly to approximatively 50% (Figure 2b-d) . Finally, as next shown on Figure 2d , cell metabolism decreased progressively as a function of time in the presence of the Bcr-Abl inhibitors and ZVAD-fmk only partially prevented it. Globally, these findings show that imatinib and PD166326-treated K562 cells can be only partly rescued from the loss of cell metabolism in the presence of the caspase inhibitor, strongly suggesting that apoptosis is only one of the mechanisms used by these drugs to affect cell viability. Therefore, the drug-induced drop of cell metabolism occurred by both caspase-dependent and -independent mechanisms.
Caspase inhibitors prevented Bcr-Abl inhibitor-mediated apoptosis but not erythroid differentiation of CML cell lines We have previously shown that imatinib induced K562 cells to differentiate towards the erythroid lineage (Jacquel et al., 2003 judged by RT-PCR analysis of erythroid markers (Jacquel et al., 2003; Jacquel et al., 2006) . We took advantage of this property to analyse the effect of SB202190 on imatinib-mediated apoptosis and erythroid differentiation using flow cytometry. K562 cells were incubated with or without 10 mM SB202190 and then treated with imatinib for 48 h in either the presence or the absence of ZVAD-fmk. SB202190 alone or in shRNAi silencing of caspase 3 blocked imatinib and PD166326-triggered caspase activation but had no effect on erythroid differentiation Caspase 3 has been reported to play a role in erythropoiesis, more particularly in the early stages of the differentiation process in the bone marrow (Carlile et al., 2004) . Thus, we thought to determine whether Bcr-Abl, apoptosis and erythroid differentiation A Jacquel et al caspase 3 was involved in the Bcr-Abl-mediated cell death and differentiation programs in K562 cells. To this aim, we generated several K562 clones inducible for the expression of shRNAi directed against caspase 3. Following stimulation with tetracycline for 5 days, caspase 3 expression could be specifically abrogated (Figure 8a ). Silencing of caspase 3 was found to drastically inhibit imatinib-induced Ac-DEVD-ase activity as compared to control K562 cells (Figure 8a) . The very low level of residual activity likely reflected a low rate of cleavage of the substrate by other executionary caspases. Caspase 3 silencing only partially increased cell metabolism in cells treated by Bcr-Abl inhibitors (Figure 8b ), suggesting the existence of a substantial caspase-independent component in the effect of Bcr-Abl inhibitors on cell metabolism. By contrast, caspase 3 silencing did not affect imatinib and PD166326-induced GPA expression and hemoglobin accumulation ( Figure 8c and data not shown), confirming that BcrAbl inhibitor-mediated apoptosis and differentiation are independent processes. Taken together, our results also demonstrate that caspase 3 activity is required for BcrAbl-mediated cell death but dispensable for erythroid differentiation of the K562 cell line.
shRNAi silencing of Bcr-Abl mimicked the effects of imatinib and PD166326 on cell death and differentiation Besides their well-documented effects as Bcr-Abl inhibitors, imatinib and PD166326 may also affect other kinases such as c-Kit, the platelet derived growth factor (PDGF) receptor and, to a less extent, Src kinases (Buchdunger et al., 2000; Heinrich et al., 2000; Huron et al., 2003) . To specifically assess the role of Bcr-Abl inhibition in the cell death and differentiation programs of K562 cells, we generated several clones inducible for the expression of a shRNAi directed against Bcr-Abl. Stimulation with tetracycline for 7 days efficiently inhibited Bcr-Abl expression (Figure 9a ). Bcr-Abl silencing resulted in the induction of apoptosis, which culminates in caspase 3 activation and could be abrogated by ZVAD-fmk. BcrAbl silencing drastically decreased cell metabolism, to 30 and 5%, respectively, at day 5 and 7 following tetracycline addition. As previously shown for caspase 3 silencing, ZVAD-fmk was found to only partially rescue K562 cells from loss of cell metabolism (Figure 9b ). Interestingly, reduced Bcr-Abl expression correlated with increased erythroid differentiation as assessed by GPA expression (Figure 9c and d) . ZVAD-fmk efficiently blocked caspase activation and apoptosis and allowed most of K562 cells to differentiate towards the erythroid lineage. Identical results were obtained using several other K562 cell clones (not shown). These findings demonstrated that Bcr-Abl silencing reproduced the effect of Bcr-Abl inhibitors on cell death and differentiation of CML cell lines.
Discussion
The present study reports that Bcr-Abl inhibitormediated apoptosis and erythroid differentiation, which proceed concomitantly in several CML cell lines, are Figure 8 Inhibition of caspase 3 expression by shRNAi does not modify the capacity of K562 cells to differentiate towards the erythroid lineage. After a 5-day pretreatment with 1 mg/ml tetracycline to allow optimal extinction of caspase 3, K562 and caspase 3 shRNAi K562 (tet-on) cells were cultured for 48 h in the presence of 1 mM imatinib, 10 nM PD166326, 1 mg/ml tetracycline or the combination of imatinib þ tetracycline or PD166326 þ tetracycline. (a) Caspase activity was assessed as previously described. Results are expressed as nanomoles of substrates per minute per milligram of protein and represent the mean7s.d. of four different determinations. Cell lysates were also analysed by SDS-PAGE on 10% polyacrylamide gels. Proteins were then transferred onto PVDF membranes and blotted with either anti-caspase 3 or anti-Hsp60 antibodies. (b) Cell metabolism was determined by the XTT assay as described previously. Results are the mean7s.d. of three independent experiments made in quadruplicate. (c) After 48 h, K562 and caspase 3 shRNAi K562 cells were labeled with an anti-GPA-PE monoclonal antibody and fluorescence was analysed by using the FL1 channel of a FACScan.
Bcr-Abl, apoptosis and erythroid differentiation A Jacquel et al fully distinguishable processes. This conclusion relies on the following observations: (i) suppression of apoptosis by ZVAD-fmk, a pancaspase inhibitor, does not prevent imatinib or PD166326-induced erythroid differentiation of K562 cells; (ii) SB202190, an inhibitor of the p38 MAP kinase pathway, efficiently blocks Bcr-Abl inhibitor-mediated erythroid differentiation without altering apoptosis; (iii) several K562 cell clones generated for their resistance to the induction of apoptosis by imatinib and PD166326 exhibited normal erythroid differentiation as compared to their parental counterparts; (iv) caspase 3 silencing in K562 cells using stably transfected and inducible shRNAi that abrogates caspase 3 expression and activity has no effect on Bcr-Abl inhibitor-mediated erythroid differentiation and finally (v) inducible Bcr-Abl silencing reproduced accurately the effects of Bcr-Abl inhibitors on cell death and differentiation of K562 cells, demonstrating the involvement of Bcr-Abl in both processes. Taken together, our results also show that erythroid differentiation does not require caspase activation at least in some CML lines. The pathway by which chemotherapeutic agents such as imatinib trigger erythroid differentiation of CML cell lines remains unclear. A possible mechanism would be that stress conditions favor erythroid differentiation. However, this is unlikely the case in the present study, as stressing K562 cells with a large panel of effectors does not consistently lead to erythroid differentiation (not shown). Moreover, we failed to find any correlation between stress-induced caspase activation and differentiation in most of cases. Finally, imatinib-induced caspase activation and differentiation were unaffected by antioxidants, suggesting that reactive oxygen species production is not involved in these processes (not shown). A recent study by Okada et al. (2004) reported that imatinib-induced cell death in CML cells occurs by both caspase-dependent and -independent mechanisms. The partial caspase independence of Bcr-Abl inhibitors is confirmed in our study by the observation that even in the presence of ZVAD-fmk, a significant loss of cell metabolism (around 50%) could be still detected upon imatinib and PD166326 treatment of CML cell lines. These results strongly suggest that other types of cell death and/or growth arrest may contribute to the effect of Bcr-Abl inhibitors on cell metabolism. This finding is also reinforced by the observation of a diminished cell rate proliferation in K562 clones, nevertheless resistant in term of apoptosis to Bcr-Abl inhibitors. The caspaseindependent counterpart of the imatinib-induced cell death could be likely owing to activation of HtrA serine peptidase 2 (HTRA2) as described recently (Okada et al., 2004) or to other currently unrevealed mechanisms. However, in our hands, neither tosyl-L-lysine chloromethylketone, a general trypsin-like inhibitor, nor the more specific OMI/HTRA2 inhibitor, UFC101, were able to further increase cell metabolism in the presence of Bcr-Abl inhibitors.
To our knowledge, this is the first report that studies specifically the relationship between cell death and differentiation in CML cell lines. This led us to develop several K562 cell clones that exhibited variable levels of imatinib and PD166326 resistance. Globally, these K562 cell variants are highly resistant to Bcr-Abl inhibitorinduced caspase activation and apoptosis, but are perfectly able to differentiate towards the erythroid lineage in response to these drugs, confirming that BcrAbl inhibitor-mediated apoptosis and differentiation are unrelated processes.
To definitely eliminate a possible implication of caspases in Bcr-Abl inhibitor-induced erythroid differentiation of K562 cells, we derived several stable K562 clones in which caspase 3 or caspase 9 (not shown) silencing can be achieved by inducible shRNAi. Although caspase 3 and 9 expression and Bcr-Abl inhibitor-induced caspase activity can be selectively abrogated in these cell lines upon tetracycline treatment, erythroid differentiation does occur in the presence of the drugs ruling out the involvement of these two caspases in this process.
Several recent studies have demonstrated the ability of small interfering RNAs to reduce Bcr-Abl expression in CD34 þ cells from CML patients (Scherr et al., 2003; Rangatia and Bonnet, 2005) and different established cell lines including the K562 CML cell line (Wohlbold et al., 2003; Rangatia and Bonnet, 2005; Withey et al., 2005) , conferring increased sensitivity to apoptosis. So we thought to determine, using inducible shRNA interference, whether Bcr-Abl silencing could mimic the effect of imatinib and PD166326 on K562 cell death and differentiation. This was of importance as it was not known whether Bcr-Abl inhibitor-mediated apoptosis and differentiation both relied on Bcr-Abl inhibition. We found that incubation of K562 cells for 5-7 days in the presence of tetracycline efficiently inhibited Bcr-Abl expression, an event accompanied by caspase activation and erythroid differentiation as shown by fluorescenceactivated cell sorting (FACS) analysis of GPA expression and specific caspase assays. Interestingly, as previously shown for Bcr-Abl inhibitors, blockade of caspase activity with ZVAD-fmk abrogates tetracyclineinduced caspase 3 activation and allows all the surviving cells to differentiate towards the erythroid lineage. Identical results were obtained with three different K562 cell clones and an excellent correlation between residual level of Bcr-Abl expression and sensitivity to apoptosis was evidenced (not shown). Very recently, Rangatia and Bonnet (2005) reached the same conclusions using transient or long-term silencing of Bcr-Abl in K562 cells and samples from CML patients. Our present study provides thus the first example of stable and inducible CML cell lines in which Bcr-Abl silencing leads to both massive apoptosis and erythroid differentiation. Interestingly, we also show that silencing BcrAbl reproduced accurately the effects of Bcr-Abl inhibitors such as imatinib or PD166326 on cell death and differentiation. Finally, this observation also indicates that although different signaling pathways are involved in both processes, Bcr-Abl inhibition is critical for both apoptosis and erythroid differentiation at least concerning the K562 cell line.
As previously mentioned, imatinib and PD166326 targeted the Bcr-Abl protein that is responsible for CML in humans. As a consequence, the main survival pathways including Erk1/2, PI3K, JAK/STAT and the NF-kB cascade are all altered by the inhibitor. By contrast, several pieces of evidence indicate that imatinib induced activation of the p38 MAP kinase pathway and that could be important for the differentiation of CML cells towards the erythroid lineage (Kohmura et al., 2004; Parmar et al., 2004) . In a recent study, Parmar et al. reported that imatinib inhibited the growth of leukemic myeloid progenitors from CML patients in a p38 MAP kinase-dependent manner. The fact that SB202190 fails to inhibit the apoptotic effect of imatinib on K562 cells despite a strong inhibition of erythroid differentiation is another argument demonstrating that imatinib-induced differentiation and apoptosis of CML cell lines are two independent processes. At present, it is not known whether Bcr-Abl inhibition by imatinib interferes with p38 MAP kinase but the different K562 cell clones generated in the present study offer an excellent opportunity to analyse how Bcr-Abl silencing leads to p38 MAP kinase activation.
Increasing evidence indicates that besides their wellestablished function in apoptosis, caspases could play important regulatory function in proliferation and differentiation of hematopoietic cells and cells from other origin (Perfettini and Kroemer, 2003; Carlile et al., 2004; Launay et al., 2005) . More specifically, caspases have been shown to be required for early-stage erythropoiesis. Of note, Carlile et al. reported that inhibition of caspase by RNA interference blocked cells at the proerythroblast stage, suggesting that caspases are involved in the stages of erythropoiesis encompassing burst forming unit erythroid differentiation to proerythroblast. Clearly, at least in the CML models used in our study, erythroid differentiation can perfectly occur in the presence of caspase inhibitors. Moreover, inhibiting apoptosis by ZVAD-fmk allows the surviving cells to differentiate towards the erythroid lineage. Thus, to some extent, caspase inhibition favors erythroid differentiation. Finally, in agreement with our present findings, Krauss et al. recently reported that late-stage erythropoiesis does not involve caspase-dependent mechanisms (Krauss et al., 2005) .
In conclusion, we demonstrate for the first time that Bcr-Abl-mediated apoptosis and erythroid differentiation are two independent processes which can be fully distinguished notably regarding their sensitivity to caspase and p38 MAP kinase inhibition. The K562 cell lines, which are now at our disposal, will represent invaluable tools to dissect at the molecular and cellular level the role of individual caspases and of Bcr-Abl on the cell death and differentiation programs of established CML cell lines. Finally, the results presented here might have interesting therapeutic implication in the treatment of CML. Indeed, induction of erythroid differentiation may be useful for those CML patients who are resistant to imatinib. Moreover, drugs that modulate the p38 MAP kinase pathway should exhibit some therapeutic benefit in such patients.
Materials and methods
Reagents and antibodies
Imatinib (STI571, Gleevec) and PD166326 were kindly provided by Novartis Pharma (Basel, Switzerland) and Pfizer (Groton, CT, USA), respectively. Roswell Park Memorial Institute 1640 (RPMI 1640) medium and fetal calf serum (FCS) were purchased from Gibco BRL (Paisley, UK). Sodium fluoride, sodium orthovanadate, phenylmethylsulfonyl fluoride (PMSF), aprotinin and leupeptin were purchased from Sigma (Saint Louis, MO, USA). SB202190 was from Calbiochem (La Jolla, CA, USA). Ac-Asp-Glu-Val-Asp-pNA (para-nitroaniline), Ac-DEVD-AMC (7-amino-4methylcou-marin), Ac-DEVD-CHO and ZVAD-fmk (ZVAD) were from Alexis Biochemicals (Lausan, Switzerland). Anti-caspase 3 and anti-Hsp60 antibodies were purchased from Transduction Laboratories (Lexington, KY, USA) and Santa Cruz Biotechnology (Santa Cruz, CA, USA), respectively. HRP-conjugated anti-mouse and anti-goat antibodies were from Dakopatts (Glostrup, Denmark).
Cell lines
The human chronic myelogenous leukaemia cells K562 and JURL-MK1 were grown at 371C under 5% CO 2 in RPMI 1640 medium (Gibco BRL, Paisley, UK) supplemented with 5 or 10% FCS (Gibco BRL, Paisley, UK), 50 U/ml penicillin, 50 mg/ml streptomycin and 1 mM sodium pyruvate. From the K562 cell line, we established resistant clones by addition in the culture medium of increasing concentrations of imatinib (up to 8 mM) and PD166326 (up to 10 nM). Ten clones either resistant to imatinib or to PD166326 were selected by limiting dilutions. For convenience, only the results obtained with two of these clones resistant, respectively, to imatinib (IIIF5 or imatinib R) and PD166326 (IVH2 or P166326 R) are presented.
Caspase activity measurement
After stimulation, cells were lysed for 30 min at 41C in lysis buffer (50 mM HEPES pH 8, 150 mM NaCl, 20 mM ethylene diaminetetraacetic acid (EDTA), 1 mM PMSF, 10 mg/ml leupeptin, 10 mg/ml aprotinin and 0.2% Triton X-100), and lysates were cleared at 10 000 g for 15 min at 41C. Each assay (in triplicate) was performed with 50 mg of protein prepared from control or stimulated cells. Briefly, cellular extracts were then incubated in a 96-well plate, with 0.2 mM of Ac-DEVDpNA or Ac-DEVD-AMC as substrates for various times at 371C as previously described (Herrant et al., 2004) . Caspase activity was measured either following absorbance at 405 nm or emission at 460 nm (excitation at 390 nm) in the presence or not of 10 mM of Ac-DEVD-CHO. Enzyme activities were determined as initial velocities expressed as nanomoles of pNa released per minute and per milligram of protein or relative intensity per minute and per milligram of protein.
Cell viability (XTT) Cells (15 Â 10 3 cells/100 ml) were incubated in a 96-well plate with different effectors for the times indicated in the figure legends. In total, 50 ml of XTT reagent (sodium 3 0 -[1-(phenylaminocarbonyl)-3,4-tetrazolium]-bis(4-methoxy-6-nitro) benzene sulfonic acid hydrate) was added to each well. The assay is based on the cleavage of the yellow tetrazolium salt XTT to form an orange formazan dye by metabolically active cells. The absorbance of the formazan product, reflecting cell viability, was measured at 490 nm. Each assay was performed in quadruplicate.
Benzidine staining and phase contrast microscopy Cell hemoglobinization was analysed by benzidine staining. In total, 1000 ml of (0.5-1 Â 10 6 cells/ml) was mixed with 200 ml benzidine dihydrochloride reagent (Sigma, Saint Louis, MO, USA). Morphological changes characteristic of erythroid differentiation were visualized using standard phase optics (Zeiss, Oberkochen, Germany).
Flow cytometry
After stimulation, cells were washed with ice-cold phosphatebuffered saline (PBS) and incubated at 41C for 30 min in 100 ml of PBS containing 0.1% bovine serum albumin (BSA) with anti-GPA-PE monoclonal antibody. After one wash with PBS, cells were fixed and permeabilized with Cytofix/Cytopermt solution. After two washes with Perm/Washt solution at room temperature, cells were incubated for 30 min with anti-activecaspase 3-FITC monoclonal antibody. Finally, cells were washed and resuspended in Perm/Washt solution. All reagents were from BD Bioscience (San Diego, CA, USA). In some experiments, control cells or Bcr-Abl inhibitorstreated cells were incubated for 48 h in the presence or absence of ZVAD-fmk and stained with the annexin-V-fluos staining kit (Roche, Meylan, France) according to the manufacturer's procedure. Fluorescence was measured by using the FL1 and FL2 channels of a FACS apparatus (FACScan, Becton Dickinson, Cowley, UK).
RT-PCR Analysis
After cell treatment, total RNAs were isolated using Trizol Reagent (Invitrogen, Cergy Pontoise, France). The supernatant was cleared by centrifugation, precipitated with isopropanol, and resuspended in RNAse and DNAsefree water. Total RNA (5 mg) was reverse transcribed using the SuperScript II reverse transcriptase (Invitrogen, Cergy Pontoise, France) following the manufacturer's instructions in a 40 ml final volume. cDNAs (2 ml) were amplified in a final volume of 10 ml using 1 U of Taq polymerase (New England Biolabs, Ipswich, MA, USA), containing buffer with 1.5 mM MgCl 2 , 0.2 mM deoxynucleoside triphosphate (dNTP) and 0.5 mM of the forward and reverse following primers: Globin alpha-s: CTGGAGAGGATGTTCCTGTCCTTG Globin alpha-as: CAGCTTAACGGTATTTGGAGGTCAT Globin zeta-s: ACCAAGACTGAGAGGACCATCATTA Globin zeta-as: TCAGGACAGAGGATACGACCGATAC GPA-s: GGAATTCCAGCTCATGATCTCAGGATG GPA-as: TCCACATTTGGTTTGGTGAACAGATTC Actin-s: ACCCACACTGTGCCCATCTTA Actin-as: CTAGAAGCATTTGCGGTGGA.
Caspase 3 and Bcr-Abl shRNAi siRNA-expressing plasmids were constructed targeting a specific region of human caspase 3 (5 0 -AGTGAAGCAAAT-CAGAAAC-3 0 ) (Carlile et al., 2004) or human BCR-ABL (5 0 -AGCAGAGTTCAAAAGCCCT-3 0 ) (Scherr et al., 2003) . The oligonucleotides purchased from Eurogentec s.a. (Seraing, Belgium) were annealed and cloned into the pTER vector (a generous gift from Dr Hans Clevers at the Hubrecht Laboratory, Utrecht, The Netherlands) using the BglII and HindIII restriction sites (van de Wetering et al., 2003) . This result in a tet-inducible shRNA expression system when stably co-transfected into K562 (tet-on) cells with the pcDNA6/TR vector (Invitrogen Ltd, Paisley, UK).
Western blot assays
After stimulation, cells were lysed for 30 min at 41C in lysis buffer (50 mM HEPES pH 7.4, 150 mM NaCl, 20 mM EDTA, 100 mM NaF, 10 mM Na 3 VO 4 , 1 mM PMSF, 10 mg/ml leupeptin, 10 mg/ml aprotinin, and 1% Triton X-100). Lysates were centrifuged at 10 000 g for 10 min at 41C and supernatants were supplemented with concentrated sodium dodecyl sulfate (SDS) sample buffer. A total of 100 mg of protein were separated on 12% polyacrylamide gel and transferred onto polyvinylidine fluoride (PVDF) membrane (Immobilon-P, Millipore, Bedford, MA, USA) in a 20 mM Tris, 150 mM glycine and 20% methanol buffer at 500 mA during 4 h at 41C. After blocking nonspecific binding sites in saturation buffer (50 mM Tris pH 7.5, 50 mM NaCl, 0.15% Tween, 5% BSA), the membranes were incubated with specific antibodies. The membranes were washed three times using Tris 50 mM pH 7.5, NaCl 150 mM, 1% NP-40 incubated further with HRP-conjugated antibody for 1 h at room temperature. Immunoblots were revealed using the enhanced chemiluminescence detection kit (Amersham Biosciences, Uppsala, Sweden).
